Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report
· 2025
Links
DOI
Journal
Unknown Journal